Zoetis offers upbeat annual outlook as Q1 results trump estimates; shares up

Published 06/05/2025, 12:38
© Reuters

Investing.com -- Zoetis (NYSE:ZTS) shares climbed more than 2% in premarket trading Tuesday after the pets and livestock drugmaker offered full-year guidance and reported first-quarter results that beat average analyst expectations.

The company reported Q1 earnings per share (EPS) of $1.48, ahead of the consensus estimate of $1.41. Revenue rose 1.4% year-over-year to $2.22 billion, just above the consensus projection of $2.20 billion.

“Zoetis achieved strong results for the first quarter of 2025, driven by demand for our innovative products and our focus on delivering for our customers. It is a testament to our colleagues’ unwavering dedication and excellence in agility that we reported organic operational revenue growth of 9%," said Kristin Peck, CEO of Zoetis.

"While the external environment continues to evolve, we remain agile, disciplined and focused on supporting our customers and the animals in their care while continuing our commitment to deliver value to shareholders.”

For full-year 2025, the company now expects earnings per share between $6.20 and $6.30, ahead of the $6.06 consensus. Revenue is projected to range from $9.425 billion to $9.575 billion, also better than the $9.329 billion forecasted by analysts.

Zoetis updated its full-year revenue outlook to reflect foreign exchange impacts but maintained its guidance for 6% to 8% organic operational growth. The company also revised its forecast for adjusted net income growth to 5% to 7%, citing the effect of enacted tariffs.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.